Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease

被引:90
作者
Jiménez-Jiménez, FJ
Molina, JA
Aguilar, MV
Meseguer, I
Mateos-Vega, CJ
González-Muñoz, MJ
de Bustos, F
Martínez-Salio, A
Ortí-Pareja, M
Zurdo, M
Martínez-Para, MC
机构
[1] Univ Alcala de Henares, Hosp Principe Asturias, Dept Neurol, Alcala De Henares, Madrid, Spain
[2] Univ Alcala de Henares, Hosp Doce Octubre, Dept Neurol, Alcala De Henares, Madrid, Spain
[3] Univ Alcala de Henares, Hosp Doce Octubre, Dept Biochem, Alcala De Henares, Madrid, Spain
[4] Univ Alcala de Henares, Fac Pharm, Dept Nutr & Bromatol, Alcala De Henares, Madrid, Spain
关键词
Parkinson's disease; transition metals; iron; copper; manganese; zinc; cerebrospinal fluid levels; serum levels;
D O I
10.1007/s007020050073
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We compared CSF and serum levels of iron, copper, manganese, and zinc, measured by atomic absorption spectrophotometry, in 37 patients with Parkinson's disease (PD) and 37 matched controls. The CSF levels of zinc were significantly decreased in PD patients as compared with controls (p < 0.05). The serum levels of zinc, and the CSF and serum levels of iron, copper, and manganese, did not differ significantly between PD-patient and control groups. There was no influence of antiparkinsonian therapy on CSF levels of none of these transition metals. These values were not correlated with age, age at onset, duration of the disease, scores of the Unified Parkinson Disease Rating Scale of the Hoehn and Yahr staging in the PD group, with the exception of CSF copper levels with the duration of the disease (r = 0.38, p < 0.05). These results suggest that low CSF zinc concentrations might be related with the risk for PD, although they could be related with oxidative stress processes.
引用
收藏
页码:497 / 505
页数:9
相关论文
共 40 条
[21]   PARKINSONISM - ONSET PROGRESSION AND MORTALITY [J].
HOEHN, MM ;
YAHR, MD .
NEUROLOGY, 1967, 17 (05) :427-&
[22]   WHAT FEATURES IMPROVE THE ACCURACY OF CLINICAL-DIAGNOSIS IN PARKINSONS-DISEASE - A CLINICOPATHOLOGICAL STUDY [J].
HUGHES, AJ ;
BENSHLOMO, Y ;
DANIEL, SE ;
LEES, AJ .
NEUROLOGY, 1992, 42 (06) :1142-1146
[23]  
JIMENEZJIMENEZ FJ, 1992, J NEUROL SCI, V112, P30
[24]   SERUM AND URINARY MANGANESE LEVELS IN PATIENTS WITH PARKINSONS-DISEASE [J].
JIMENEZJIMENEZ, FJ ;
MOLINA, JA ;
AGUILAR, MV ;
ARRIETA, FJ ;
JORGESANTAMARIA, A ;
CABRERAVALDIVIA, F ;
AYUSOPERALTA, L ;
RABASA, M ;
VAZQUEZ, A ;
GARCIAALBEA, E ;
MARTINEZPARA, MC .
ACTA NEUROLOGICA SCANDINAVICA, 1995, 91 (05) :317-320
[25]  
JIMENEZJIMENEZ FJ, 1996, NEUROLOGIA S3, V11, P93
[26]   CEREBROSPINAL-FLUID FERRITIN LEVELS OF PATIENTS WITH PARKINSONS-DISEASE, ALZHEIMERS-DISEASE, AND MULTIPLE SYSTEM ATROPHY [J].
KUIPER, MA ;
MULDER, C ;
VANKAMP, GJ ;
SCHELTENS, P ;
WOLTERS, EC .
JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION, 1994, 7 (02) :109-114
[27]   DISTRIBUTION OF ARSENIC, MANGANESE, AND SELENIUM IN THE HUMAN-BRAIN IN CHRONIC RENAL-INSUFFICIENCY, PARKINSONS-DISEASE, AND AMYOTROPHIC LATERAL SCLEROSIS [J].
LARSEN, NA ;
PAKKENBERG, H ;
DAMSGAARD, E ;
HEYDORN, K ;
WOLD, S .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1981, 51 (03) :437-446
[28]   CERULOPLASMIN IS INCREASED IN CEREBROSPINAL-FLUID IN ALZHEIMERS-DISEASE BUT NOT PARKINSONS-DISEASE [J].
LOEFFLER, DA ;
DEMAGGIO, AJ ;
JUNEAU, PL ;
BRICKMAN, CM ;
MASHOUR, GA ;
FINKELMAN, JH ;
POMARA, N ;
LEWITT, PA .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1994, 8 (03) :190-197
[29]   Altered systemic iron metabolism in Parkinson's disease [J].
Logroscino, G ;
Marder, K ;
Graziano, J ;
Freyer, G ;
Slavkovich, V ;
LoIacono, N ;
Cote, L ;
Mayeux, R .
NEUROLOGY, 1997, 49 (03) :714-717
[30]   OXYGEN-TOXICITY PROTECTING ENZYMES IN PARKINSONS-DISEASE - INCREASE OF SUPEROXIDE DISMUTASE-LIKE ACTIVITY IN THE SUBSTANTIA NIGRA AND BASAL NUCLEUS [J].
MARTTILA, RJ ;
LORENTZ, H ;
RINNE, UK .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1988, 86 (2-3) :321-331